These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 19306629)

  • 1. [Hemostatic management for cardiac surgical patients in the post-aprotinin era].
    Tanaka K
    Masui; 2009 Mar; 58(3):288-97. PubMed ID: 19306629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mortality associated with aprotinin during 5 years following coronary artery bypass graft surgery.
    Mangano DT; Miao Y; Vuylsteke A; Tudor IC; Juneja R; Filipescu D; Hoeft A; Fontes ML; Hillel Z; Ott E; Titov T; Dietzel C; Levin J; ;
    JAMA; 2007 Feb; 297(5):471-9. PubMed ID: 17284697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The safety of aprotinin and lysine-derived antifibrinolytic drugs in cardiac surgery: a meta-analysis.
    Henry D; Carless P; Fergusson D; Laupacis A
    CMAJ; 2009 Jan; 180(2):183-93. PubMed ID: 19050037
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological strategies to decrease excessive blood loss in cardiac surgery: a meta-analysis of clinically relevant endpoints.
    Levi M; Cromheecke ME; de Jonge E; Prins MH; de Mol BJ; Briët E; Büller HR
    Lancet; 1999 Dec; 354(9194):1940-7. PubMed ID: 10622296
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Coronary artery bypass grafting after aprotinin: are we doing better?
    Beckerman Z; Shopen Y; Alon H; Cohen O; Nir RR; Adler Z; Bolotin G
    J Thorac Cardiovasc Surg; 2013 Jan; 145(1):243-8. PubMed ID: 23072702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased recombinant activated factor VII use and need for surgical reexploration following a switch from aprotinin to epsilon-aminocaproic acid in infant cardiac surgery.
    Scott JP; Costigan DJ; Hoffman GM; Simpson PM; Dasgupta M; Punzalan R; Berens RJ; Tweddell JS; Stuth EA
    J Clin Anesth; 2014 May; 26(3):204-11. PubMed ID: 24809789
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tranexamic acid and aprotinin in primary cardiac operations: an analysis of 220 cardiac surgical patients treated with tranexamic acid or aprotinin.
    Dietrich W; Spannagl M; Boehm J; Hauner K; Braun S; Schuster T; Busley R
    Anesth Analg; 2008 Nov; 107(5):1469-78. PubMed ID: 18931201
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The risk associated with aprotinin in cardiac surgery.
    Mangano DT; Tudor IC; Dietzel C; ;
    N Engl J Med; 2006 Jan; 354(4):353-65. PubMed ID: 16436767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intraoperative antifibrinolysis and blood-saving techniques in cardiac surgery. Prospective trial of 3 antifibrinolytic drugs.
    Penta de Peppo A; Pierri MD; Scafuri A; De Paulis R; Colantuono G; Caprara E; Tomai F; Chiariello L
    Tex Heart Inst J; 1995; 22(3):231-6. PubMed ID: 7580360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Aprotinin in cardiac surgery: more risks than usefulness?].
    Bremerich DH; Strametz R; Kirchner R; Moritz A; Zwissler B
    Anaesthesist; 2006 Sep; 55(9):989-92, 994-6. PubMed ID: 16874472
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lessons from the aprotinin saga: current perspective on antifibrinolytic therapy in cardiac surgery.
    Ide M; Bolliger D; Taketomi T; Tanaka KA
    J Anesth; 2010 Feb; 24(1):96-106. PubMed ID: 20039075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tranexamic acid compared with high-dose aprotinin in primary elective heart operations: effects on perioperative bleeding and allogeneic transfusions.
    Casati V; Guzzon D; Oppizzi M; Bellotti F; Franco A; Gerli C; Cossolini M; Torri G; Calori G; Benussi S; Alfieri O
    J Thorac Cardiovasc Surg; 2000 Sep; 120(3):520-7. PubMed ID: 10962414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Con: Aprotinin should not be used in cardiac surgery with cardiopulmonary bypass.
    Augoustides JG
    J Cardiothorac Vasc Anesth; 2007 Apr; 21(2):302-4. PubMed ID: 17418754
    [No Abstract]   [Full Text] [Related]  

  • 14. Antifibrinolytic agents and desmopressin as hemostatic agents in cardiac surgery.
    Erstad BL
    Ann Pharmacother; 2001 Sep; 35(9):1075-84. PubMed ID: 11573859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Which may be effective to reduce blood loss after cardiac operations in cyanotic children: tranexamic acid, aprotinin or a combination?
    Bulutcu FS; Ozbek U; Polat B; Yalçin Y; Karaci AR; Bayindir O
    Paediatr Anaesth; 2005 Jan; 15(1):41-6. PubMed ID: 15649162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of aprotinin in cardiac surgery.
    Levy JH
    Orthopedics; 2004 Jun; 27(6 Suppl):s659-62. PubMed ID: 15239553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of aprotinin, tranexamic acid, and aminocaproic acid on blood loss and use of blood products in major pediatric surgery: a meta-analysis.
    Schouten ES; van de Pol AC; Schouten AN; Turner NM; Jansen NJ; Bollen CW
    Pediatr Crit Care Med; 2009 Mar; 10(2):182-90. PubMed ID: 19188875
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The current place of aprotinin in the management of bleeding.
    Royston D
    Anaesthesia; 2015 Jan; 70 Suppl 1():46-9, e17. PubMed ID: 25440394
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The risk-benefit profile of aprotinin versus tranexamic acid in cardiac surgery.
    Karkouti K; Wijeysundera DN; Yau TM; McCluskey SA; Tait G; Beattie WS
    Anesth Analg; 2010 Jan; 110(1):21-9. PubMed ID: 19910626
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aprotinin dosing: how much is enough?
    Niimi KS
    J Extra Corpor Technol; 2004 Dec; 36(4):384-90. PubMed ID: 15679284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.